An increasing number of people are discovering fatty liver during routine ultrasound tests, often without any obvious symptoms. Doctors explain what this finding really means, why it is becoming more ...

Background Metabolic-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease affecting approximately ...

Elexacaftor-tezacaftor-ivacaftor combination therapy shows no clinically meaningful improvement in bone health or calcium metabolism in patients with cystic fibrosis, a Danish study shows.

New research shows an AI-driven liquid biopsy analyzing genome-wide cfDNA fragment patterns can detect early liver fibrosis & cirrhosis and may signal broader chronic disease burden.

Randomized trial shows no difference from sham control ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:00 AM EDTCompany ParticipantsAndrew Obenshain - CEO ...

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 ...

Resmetirom improved HRQOL versus placebo in early MASH, particularly abdominal symptoms, disease-related worry, and health distress, with onset by week 24 and durability through week 52. Baseline ...

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...

Findings from a phase 1/2 trial (NCT04176) presented at the 2025 American Society of Hematology Annual Meeting and Exposition ...

BACKGROUND: Peripheral artery disease (PAD) and its severe form, chronic limb-threatening ischemia (CLTI), significantly impair blood flow to the lower extremities, affecting millions of adults ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.